iii) wherein the first amino acid sequence is SEQ ID NO: 3 or said derivative thereof, and wherein the second amino acid sequence is SEQ ID NO: 100, in particular wherein said polypeptide comprises additionally the amino acid sequence of SEQ ID NO: 104 or a derivative thereof exhibiting at least 80% sequence identity with SEQ ID NO: 104.

10. The polypeptide according to any one of the preceding claims, wherein the polypeptide degrades the peptidoglycan of Enterococcus bacteria, in particular of *Enterococcus faecalis* and/or *Enterococcus faecium* bacteria.

11. The polypeptide according to claim 10, wherein the polypeptide is at an about physiological pH, such as pH 7.4, more active than the wildtype enzyme (SEQ ID NO:1) and/or exhibits essentially the same or increased activity at about physiological pH compared to more acidic pH, such as pH 5.25 or 6.

12. A composition comprising an endolysin of any one of the preceding claims and a pharmaceutically acceptable carrier, diluent or excipient.

13. The composition according to claim 12, wherein the composition is bone cement or comprises biomaterial.

14. A polypeptide according to any one of claims 1 to 11 or a composition according to any one of claims 12 to 13 for use in a method for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body.

15. Use of the polypeptide or composition according to claim 14 in the manufacture of a medicament for the treatment or prevention of bacterial infections, in particular for the treatment or prevention of bacterial infections with *Enterococcus faecalis* and/or *Enterococcus faecium* bacteria.

16. The polypeptide or composition for use according to claim 14 or claim 15, wherein the polypeptide or composition is used at about physiological pH, e.g. at a pH of about 7.2 to 7.6, more preferably at a pH of about 7.4.